Fierce15 winner Rallybio establishes proof-of-concept in phase 1/2 study for rare fetal bleeding disorder.

2018 Fierce15 winner Rallybio has established proof-of-concept for an antibody treatment aiming to prevent a rare disease that causes a mother's immune system to attack her fetus or newborn child's platelets. Rallybio is conducting a phase 1/2 study of RLYB211 to prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), which can cause uncontrollable bleeding in fetuses and newborns. [ABSTRACT FROM AUTHOR]

Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)